Sparks commentary

Healthcare

Sparks

Biomea Fusion’s (NASDAQ: BMEA) BMF-219 trials continue
Published by Arron Aatkar, PhD

Biomea Fusion announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials, COVALENT-111 and COVALENT-112, for BMF-219, which is being evaluated as a potential new treatment for type 2 and type 1 diabetes, respectively. BMF-219 is Biomea Fusion’s lead asset and it has potential as a first-in-class agent for the treatment of diabetes, operating by a novel covalent mechanism of action. Top-line data readouts for COVALENT-111 and COVALENT-112 remain on track for Q424.

Latest

Industrials | Comment

THEON INTERNATIONAL (AMS: THEON) – additional order intake

Healthcare | Comment

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

Industrials | Comment

AAC Clyde Space (OTCQX: AAC) share issue raising SEK64.5m

Industrials | Comment

Hercules (AIM: HERC) acquire Advantage NRG for up to £15.7m

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free